Clinical trials: Diabetic Macular Edema
Diabetic Retinopathy
Routine Clinical Practice for Use of Intravitreal Aflibercept Treatment in Patients With Diabetic Macular Edema
The main objectives of this observational study were to describe outcomes, monitoring and treatment patterns of patients with diabetic macular edema in routine clinical practice who are either treatment naïve patients or…
- Trial name
- APOLLON (NCT02924311)
- Testing
- Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
- Where
- France
- Volunteers
- 402 people
- Sponsor
- Bayer
Neovascular Age-related Macular Degeneration (NVAMD), Diabetic Macular Edema (DME)
A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT) Remigromig (EYE103) in Patients With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD)
EYE103-101 is a 2-part study assessing safety and preliminary efficacy of remigromig (EYE103) in patients with diabetic macular edema (DME) given as monotherapy or neovascular macular degeneration (NVAMD) given in combination…
- Trial name
- AMARONE (NCT05919693)
- Testing
- Remigromig
- Where
- 32 sites in United States, Argentina and 2 more
- Volunteers
- 33 people
- Sponsor
- EyeBiotech Ltd.
Wet Age-related Macular Degeneration, Retinal Vein Occlusion
Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects With wAMD, DME and RVO
This is a Phase 1b open-label study to assess the bioactivity, ocular and systemic safety, tolerability, and pharmacokinetics of repeated injections of KSI-301 at two dose levels: 2.5 mg and 5 mg
- Conditions
- Wet Age-related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema
- Trial name
- NCT03790852
- Testing
- KSI-301
- Where
- 11 sites in United States
- Volunteers
- 121 people
- Sponsor
- Kodiak Sciences Inc
Neovascular Age-related Macular Degeneration (nAMD), Wet Age-related Macular Degeneration (AMD)
An Observational Study to Investigate the Use of Aflibercept 8 mg to Treat Adult Patients With Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) in a Real-World Setting
The purpose of this research study is to observe the patient's clinical care and how EYLEA® HD is used as a treatment in real-world settings.
- Conditions
- Neovascular Age-related Macular Degeneration (nAMD), Wet Age-related Macular Degeneration (AMD), Diabetic Macular Edema (DME), Visual Impairment
- Trial name
- SPECTRUM-US (NCT06398080)
- Testing
- aflibercept 8 mg
- Sponsor
- Regeneron Pharmaceuticals
Macular Edema
Efficacy and Safety of VEGF Trap Eye in Diabetic Macular Edema (DME) With Central Involvement
To determine the efficacy of intravitreally (IVT) administered VEGF Trap-Eye on the best-corrected visual acuity (BCVA) assessed by the early treatment diabetic retinopathy study (ETDRS) chart in subjects with diabetic macular…
- Trial name
- VIVID EAST (NCT01783886)
- Testing
- Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321), Macular Laser Photocoagulation
- Where
- 25 sites in China, Hong Kong and 2 more
- Volunteers
- 381 people
- Sponsor
- Bayer
Diabetic Macular Edema
A Multicenter Study to Compare Multiple Doses of Intravitreal Microplasmin Versus Sham Injection for Treatment of Patients With Diabetic Macular Edema (DME)
A multicenter study to compare multiple doses of intravitreal microplasmin for non-surgical PVD induction for treatment of patients with DME.
- Trial name
- MIVI-II (NCT00412451)
- Testing
- ocriplasmin
- Where
- 15 sites in Belgium, Germany and 4 more
- Volunteers
- 51 people
- Sponsor
- ThromboGenics
Diabetic Macular Edema
Safety Study of ALG- 1001 to Treat Diabetic Macular Edema
The objective of this study is to evaluate the safety and efficacy of ophthalmic intravitreal injection of ALG - 1001 in human subjects with diabetic macular edema.
- Trial name
- NCT01482871
- Testing
- ALG-1001
- Where
- Mexico
- Sponsor
- Allegro Ophthalmics, LLC
Diabetic Macular Edema
Chart Review: Drug Utilization Study in Participants Who Received Ozurdex™ (Dexamethasone Intravitreal Implant) 0.7 mg Injections for Visual Impairment Due to Diabetic Macular Edema (DME)
A retrospective, non-interventional, observational, multi-center, drug utilization study to be conducted in adult participants with visual impairment due to DME treated with Ozurdex implants in Germany and Switzerland from 1…
- Trial name
- NCT03889444
- Testing
- Dexamethasone intravitreal implant
- Where
- United States
- Volunteers
- 141 people
- Sponsor
- Allergan
Macular Edema
Efficacy and Safety of Three Different Aflibercept Regimens in Subjects With Diabetic Macular Edema (DME)
To evaluate the efficacy of long-term treatment with 2 mg aflibercept via different intravitreal (IVT) treatment regimens to participants with DME pretreated with 2 mg aflibercept every 8 weeks after 5 initial monthly injections…
- Trial name
- VIOLET (NCT02818998)
- Testing
- Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
- Where
- 64 sites in Austria, Canada and 12 more
- Volunteers
- 463 people
- Sponsor
- Bayer
Diabetic Macular Edema
A Study to Learn More About How Well 8 Milligram Aflibercept Works and How Safe it is in Chinese Participants With Diabetic Macular Edema
Researchers are looking for a better way to treat people who have diabetic macular edema. Diabetic macular edema (DME) is a diabetes-related eye disorder.
- Trial name
- PHOTONiC (NCT06422507)
- Testing
- 8 mg aflibercept (BAY 86-5321) (High Dose), 2 mg aflibercept (EYLEA, BAY 86-5321)
- Where
- 52 sites in China, Hong Kong
- Volunteers
- 333 people
- Sponsor
- Bayer
Diabetic Macular Edema (DME)
A Study to Evaluate the Efficacy and Safety of Tabirafusp Tedromer Compared to Aflibercept in Participants With DME - ALTO
A Study to Evaluate the Efficacy and Safety of Tabirafusp Tedromer Compared to Aflibercept in Participants with Diabetic Macular Edema - ALTO
- Trial name
- ALTO (NCT07734844)
- Testing
- Tabirafusp tedromer, Aflibercept (2.0 mg)
- Where
- 52 sites in United States, Argentina
- Volunteers
- 910 people
- Sponsor
- Kodiak Sciences Inc
Anti- VGF Inhibitor, Diabetic Macular Edema
Study To Evaluate Safety And Tolerability Of Pegaptanib Sodium In Patients With Diabetic Macular Edema
This study will asses sthe safety of pegaptanib sodium in patients with diabetic macular edema. The hypothesis is that pegaptanib is safe and efficacious in patients with diabetic macular edema.
- Conditions
- Anti- VGF Inhibitor, Diabetic Macular Edema, Diabetic Retinopathy
- Trial name
- NCT01189461
- Testing
- pegaptanib sodium
- Where
- 12 sites in Finland, Spain and 2 more
- Volunteers
- 46 people
- Sponsor
- Pfizer
Diabetic Macular Edema (DME)
A Phase 2 Study to Evaluate the Efficacy and Safety of ENN0403 in Subjects With DME
This is a multicenter, randomized, parallel study to evaluate the efficacy and safety of two doses of ENN0403 in subjects with diabetic macular edema (DME).
- Trial name
- NCT06708260
- Testing
- ENN0403, low dose, ENN0403, high dose
- Where
- 9 sites in China
- Volunteers
- 60 people
- Sponsor
- EnnovaBio
Anesthesia, Local, Intravitreal Injection
Cooling Anesthesia for Intravitreal Injection
The purpose of this clinical study is to evaluate the safety and efficacy of cooling anesthesia application to the eye as anesthesia for intravitreal injection using a novel cooling anesthesia device and determine the effects of…
- Conditions
- Anesthesia, Local, Intravitreal Injection, Macular Degeneration, Diabetic Macular Edema
- Trial name
- COOL-1 (NCT03732287)
- Testing
- Cooling Anesthesia
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Recens Medical, Inc.
Neovascular Age-related Macular Degeneration (nAMD), Diabetic Macular Edema (DME)
A Phase I Study of GenSci148 Intravitreal Injection for Neovascular Age-related Macular Degeneration, Diabetic Macular Edema and Retinal Vein Occlusion
This is a Phase I, multicenter, open-label, dose-escalation study conducted in two parts to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of GenSci148 administered via intravitreal (IVT)…
- Conditions
- Neovascular Age-related Macular Degeneration (nAMD), Diabetic Macular Edema (DME), Retinal Vein Occlusion (RVO)
- Trial name
- GenSci148-101 (NCT07817615)
- Testing
- GenSci148 Injection
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Non-proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy
Phase 2 Spectra Study to Evaluate the Safety and Efficacy of OPL-0401 in Patients With Diabetic Retinopathy
OPL-0401-201 is a multicenter study to investigate the safety and efficacy of OPL-0401 in patients with diabetes mellitus (DM) with diabetic retinopathy.
- Trial name
- NCT05393284
- Testing
- OPL-0401 Dose 1
- Where
- 25 sites in United States
- Volunteers
- 114 people
- Sponsor
- Valo Health, Inc.
Diabetic Macular Edema
Study of EYP-1901 in Patients With Diabetic Macular Edema (DME)
A prospective, randomized, single-masked study evaluating the ocular efficacy and safety of two doses of the EYP-1901 intravitreal insert compared to aflibercept
- Trial name
- VERONA (NCT06099184)
- Testing
- EYP-1901, Aflibercept 2Mg/0.05Ml Inj,Oph
- Where
- 6 sites in United States
- Volunteers
- 27 people
- Sponsor
- EyePoint Pharmaceuticals, Inc.
Diabetic Macular Edema
Effect of Ruboxistaurin on Clinically Significant Macular Edema
The purpose of the study is to test the hypothesis that oral administration of ruboxistaurin will reduce the occurrence of sustained moderate visual loss (SMVL) in patients with clinically significant macular edema.
- Trial name
- NCT00133952
- Testing
- Ruboxistaurin
- Where
- 41 sites in United States, Canada and 8 more
- Volunteers
- 309 people
- Sponsor
- Chromaderm, Inc.
Diabetic Macular Edema
Evaluation of Repeated, In-Clinic, Self-Imaging by DME Patients Using the Notal Vision Home OCT
Evaluation of Repeated, In-Clinic, Self-Imaging by DME Patients Using the Notal Vision Home OCT The purpose of this study is to collect data on the NVHO device at up to three sites.
- Trial name
- NCT05745116
- Testing
- Notal Vision Home OCT
- Where
- 3 sites in United States
- Volunteers
- 150 people
- Sponsor
- Notal Vision Inc.
Diabetic Retinopathy, Diabetic Macular Edema
Study of the Safety and Efficacy of APX3330 in Diabetic Retinopathy
The objective of this study is to evaluate the safety and efficacy of APX3330 to treat diabetic retinopathy (DR) and diabetic macular edema (DME).
- Conditions
- Diabetic Retinopathy, Diabetic Macular Edema, NPDR - Non Proliferative Diabetic Retinopathy, PDR - Proliferative Diabetic Retinopathy
- Trial name
- ZETA-1 (NCT04692688)
- Testing
- APX3330
- Where
- 24 sites in United States
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- Opus Genetics, Inc